METHOD FOR THE TREATMENT OR PREVENTION OF INFECTION-RELATED IMMUNE CONDITIONS USING A COMPOSITION COMPRISING IGM

1 - 26 . (canceled)

27 . A pharmaceutical composition for the treatment of sepsis, comprising:

a composition suitable for injection comprising immunoglobulin in a pharmaceutically acceptable carrier, wherein the immunoglobulin is at least 90% IgM.

28 . The composition according to claim 27 , characterized in that sepsis is produced by Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum , or combinations thereof.

29 . The composition according to claim 27 , characterized in that treatment of sepsis is performed through immunomodulation.

30 . The composition according to claim 29 , characterized in that immunomodulation is performed through inhibition of NF-κB induction, through the inhibition of proliferation of peripheral blood mononuclear cells or combination thereof.

31 . (canceled)

32 . The composition according to claim 27 , characterized in that the composition has a 95% (w/v) of IgM purity.

33 . The composition according to claim 27 , characterized in that the dose to be administered of the composition is from 75 mg IgM/kg patient to 1 g IgM/kg patient.

34 . The composition according to claim 33 , characterized in that the composition is administered at least once a week.

35 . The composition according to claim 27 , characterized in that IgM is recombinant, plasma-derived, cell culture-derived, transgenic, or chemically synthesized.

36 . The composition according to claim 35 , IgM is plasma-derived IgM, isolated from a suitable fraction of plasma.

37 . The composition according to claim 27 , characterized in that the composition comprising IgM is administered alone.

38 . The composition according to claim 27 , characterized in that the composition comprising IgM is administered together with one or more other compositions or molecules selected from anti-inflammatory molecules, small molecule antibiotics, molecules that are antimicrobial in nature, natural or synthetic peptide antimicrobials, proteins with antimicrobial properties, other immunomodulators, or combinations thereof.

39 . The composition according to claim 38 , characterized in that said other compositions or molecules are vancomycin, meropenem, lactoferrin, or combinations thereof.

40 . A pharmaceutical composition for the treatment of immune complications produced by an infection, comprising:

a composition suitable for injection comprising immunoglobulin in a pharmaceutically acceptable carrier, wherein the immunoglobulin is at least 90% IgM.

41 . The composition according to claim 40 , characterized in that the infection is produced by Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum , or combinations thereof.

42 . The composition according to claim 40 , characterized in that treatment of immune complications is performed through immunomodulation.

43 . The composition according to claim 42 , characterized in that immunomodulation is performed through the inhibition of NF-κB induction, through the inhibition of proliferation of peripheral blood mononuclear cells or combination thereof.

44 . (canceled)

45 . The composition according to claim 40 , characterized in that the composition has a 95% (w/v) of IgM purity.

46 . The composition according to claim 40 , characterized in that the dose to be administered of the composition is from 75 mg IgM/kg patient to 1 g IgM/kg patient.

47 . The composition according to claim 46 , characterized in that the composition is administered at least once a week.

48 . The composition according to claim 40 , characterized in that IgM is recombinant, plasma-derived, cell culture-derived, transgenic, or chemically synthesized.

49 . The composition according to claim 48 , wherein the IgM is plasma-derived IgM, isolated from a suitable fraction of plasma.

50 . The composition according to claim 40 , characterized in that the composition comprising IgM is administered alone.

51 . The composition according to claim 40 , characterized in that the composition comprising IgM is administered together with one or more other compositions or molecules selected from anti-inflammatory molecules, small molecule antibiotics, molecules that are antimicrobial in nature, natural or synthetic peptide antimicrobials, proteins with antimicrobial properties, other immunomodulators, or combinations thereof.

52 . The composition according to claim 51 , characterized in that said other compositions or molecules are vancomycin, meropenem, lactoferrin, or combinations thereof.